EsoCap AG

EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds.

EsoCap, a privately funded company based in Basel, Switzerland, has developed a novel solution designed to provide targeted and long-lasting local therapy in the upper gastrointestinal tract.

What is EsoCap?

Play Video


EsoCap Recent News

“The EsoCap novel smart drug delivery technology will enable targeted and long-lasting local therapy of the esophagus for the first time. Our technology offers maximum flexibility, as multiple relevant drug substances, including biologics and further innovative compounds, can be incorporated, making our drug delivery platform applicable to various clinical indications.”

Isabelle Racamier



EsoCap AG

Malzgasse 9, CH-4052 Basel